BIBP 3226 trifluoroacetate: Precision NPY Y1/NPFF Receptor Antagonist for NPY/NPFF System Research

Executive Summary: BIBP 3226 trifluoroacetate (CAS: 1068148-47-9) is a non-peptide antagonist with nanomolar affinity for neuropeptide Y Y1 (NPY Y1) and neuropeptide FF (NPFF) receptors, facilitating targeted investigation of the NPY/NPFF neuropeptide system (APExBIO). It exhibits a Ki of 1.1 nM for rat NPY Y1 and 79 nM for human NPFF2, making it highly selective (Fan et al., 2024). BIBP 3226 trifluoroacetate effectively blocks NPFF-induced inhibition of cAMP production and associated hypothermic/anti-opioid effects in rodents. The compound is instrumental in studying the adipose-neural axis, especially regarding cardiac arrhythmia pathogenesis, anxiety, analgesia, and cardiovascular regulation (Fan et al., 2024). It is supplied by APExBIO as a research-grade reagent with >98% purity and validated by HPLC, MS, and NMR characterization.

Biological Rationale

The neuropeptide Y/neuropeptide FF (NPY/NPFF) system is a key regulator of anxiety, pain perception, and cardiovascular homeostasis (Fan et al., 2024). NPY Y1 receptors are expressed in the central and peripheral nervous system, and mediate effects on mood, energy balance, and autonomic output. NPFF receptors modulate pain and are implicated in opioid tolerance and anti-nociceptive pathways. Dysfunction in the NPY/NPFF axis is linked to pathological states such as cardiac arrhythmias, where adipose-neural interactions play a pivotal role. Recent stem cell-based coculture models revealed that adipocyte-derived leptin can trigger NPY release from sympathetic neurons, activating Y1 receptors in cardiomyocytes and promoting arrhythmic phenotypes (Fan et al., 2024). These insights position BIBP 3226 trifluoroacetate as a valuable tool for dissecting neuropeptide signaling in both basic and translational research contexts.

Mechanism of Action of BIBP 3226 trifluoroacetate

BIBP 3226 trifluoroacetate is a non-peptide, competitive antagonist for the NPY Y1 receptor and the NPFF receptor. It binds with high affinity to rat NPY Y1 (Ki = 1.1 nM), human NPFF2 (Ki = 79 nM), and rat NPFF (Ki = 108 nM) (APExBIO). At the cellular level, BIBP 3226 inhibits NPFF-induced suppression of forskolin-stimulated cAMP production, indicating blockade of G protein-coupled receptor (GPCR) signaling. In vivo, it prevents NPFF-dependent hypothermia and antagonizes the anti-opioid effects mediated by NPFF in rodent models. Mechanistically, BIBP 3226 interrupts downstream signaling cascades associated with NPY Y1 and NPFF receptor activation, which involve modulation of calcium signaling and protein kinases such as CaMKII—critical in arrhythmogenesis and neuro-adipose communication (Fan et al., 2024).

Evidence & Benchmarks

• BIBP 3226 trifluoroacetate demonstrates nanomolar affinity for rat NPY Y1 (Ki = 1.1 nM), enabling selective receptor antagonism (APExBIO).
• In cell-based assays, BIBP 3226 competitively inhibits NPFF-induced inhibition of cAMP accumulation in forskolin-stimulated cells (APExBIO).
• In vivo rodent studies show BIBP 3226 blocks NPFF-mediated hypothermic and anti-opioid responses, confirming pathway specificity (APExBIO).
• Fan et al. (2024) demonstrate that NPY Y1 receptor inhibition by specific antagonists, including BIBP 3226, partially suppresses arrhythmic phenotypes in adipocyte-neuron-cardiomyocyte cocultures (Fan et al., 2024).
• Elevated epicardial adipose tissue (EAT) thickness and increased leptin/NPY levels are associated with atrial fibrillation patients, highlighting the NPY Y1/NPFF axis as a therapeutic target (Fan et al., 2024).

This article updates and extends mechanistic frameworks outlined in "Dissecting the Adipose-Neural Axis: Strategic Guidance ..." by providing direct evidence from recent stem cell-based models that link the NPY/NPFF pathway to cardiac arrhythmia, and offers detailed protocol integration for BIBP 3226 trifluoroacetate.

For a practical comparison of tool compounds in cell signaling applications, see "BIBP 3226 trifluoroacetate: Resolving NPY/NPFF Pathway Challenges ...", which focuses on cell viability and proliferation assays, whereas this article emphasizes translational and mechanistic cardiac models.

Applications, Limits & Misconceptions

BIBP 3226 trifluoroacetate is employed as a reference antagonist in academic and industrial laboratories for:

• Dissecting NPY/NPFF receptor function in models of anxiety, analgesia, and cardiovascular regulation (BIBP 3226 Trifluoroacetate: Precision Tool ...).
• Mapping cAMP signaling pathways downstream of GPCRs.
• Elucidating the physiological consequences of adipose-neural axis activation in cardiac arrhythmia (Fan et al., 2024).
• Investigating the anti-opioid and hypothermic actions of NPFF in vivo.

Common Pitfalls or Misconceptions

• BIBP 3226 trifluoroacetate is not effective against NPY Y2, Y4, or Y5 receptor subtypes; its selectivity is primarily for Y1 and NPFF receptors (APExBIO).
• The compound is not intended for diagnostic or therapeutic use in humans; it is strictly for scientific research (APExBIO).
• Long-term storage of solutions can reduce activity; solutions should be freshly prepared and used promptly to maintain potency.
• Some signaling pathways modulated by NPY/NPFF may be context-dependent and not fully recapitulated in all cell lines or animal models.
• Off-target effects at very high concentrations (>10 μM) cannot be ruled out; always titrate doses for each system.

Workflow Integration & Parameters

BIBP 3226 trifluoroacetate (SKU B7155) is supplied as an off-white solid with a molecular weight of 587.59 and chemical formula C29H32F3N5O5. It is soluble at ≥78 mg/mL in DMSO, ≥73.2 mg/mL in ethanol, and ≥12.13 mg/mL in water (with ultrasonic assistance). Recommended storage is at -20°C. For use, dissolve in DMSO or ethanol for in vitro applications, ensuring final solvent concentrations do not exceed 0.1% v/v in cell-based assays. Purity is >98% by HPLC, with additional QC by MS and NMR; a Certificate of Analysis (COA) is provided by APExBIO.

In cardiac arrhythmia models, BIBP 3226 can be added to cocultures of sympathetic neurons, cardiomyocytes, and adipocytes at concentrations between 10 nM and 1 μM, depending on assay sensitivity and endpoint (Fan et al., 2024). For acute signaling assays (e.g., cAMP), lower concentrations (1–100 nM) are typically sufficient. Always validate experimental concentrations with pilot titration studies.

For comprehensive protocol optimization, see "BIBP 3226 trifluoroacetate: Reliable Antagonist for NPY/N...", which explores scenario-driven troubleshooting in cell signaling and viability assays; this article complements those guidelines with updated evidence from multi-cellular coculture platforms.

Conclusion & Outlook

BIBP 3226 trifluoroacetate is a validated, high-affinity tool for NPY Y1 and NPFF receptor pathway research, supporting advanced interrogation of the adipose-neural axis in cardiovascular, anxiety, and pain models. Its robust selectivity and compatibility with complex experimental systems make it a cornerstone reagent for translational discovery. Ongoing research leveraging BIBP 3226 trifluoroacetate will further clarify the role of neuropeptide receptor signaling in arrhythmogenesis and metabolic disease, expanding options for targeted intervention (Fan et al., 2024). For ordering or additional specifications, refer to the BIBP 3226 trifluoroacetate product page at APExBIO.